Literature DB >> 18059180

Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.

Jiezhong Chen1, Nigel A J McMillan.   

Abstract

B-cell chronic lymphocytic leukemia (CLL) is caused by the abnormal accumulation of non-functional B-cells in peripheral blood and bone marrow. However, the precise aetiology and mechanism of the disease are unclear. Recently, progress has been made in the identification of both the genetic deficiencies and environmental factors that may underlie CLL. This has provided some clues to the nature of the disease, but no definitive cures. Although treatment has increased remission time, at present the disease is not curable by conventional therapy. Further studies of the pathogenesis of CLL are needed, as are the development of suitable cell lines and animal models in which to study it. This review summarises the most recent progress in CLL with emphasis on molecular events and possible implications in therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059180     DOI: 10.4161/cbt.7.2.5262

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  10 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Comment on "effects of adipocyte-secreted factors on cell cycle progression in HT29 cells" published by Eur J Nutr.

Authors:  Jiezhong Chen; Xu-Feng Huang
Journal:  Eur J Nutr       Date:  2009-12       Impact factor: 5.614

Review 3.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

4.  Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Laura Z Rassenti; Minya Pu; Colleen Kelly; Joan R Kanter; Andrew Greaves; Karen Messer; Thomas J Kipps; Paul A Insel
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

5.  Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression.

Authors:  Qing-Min Yao; Pei-Pei Li; Shu-Mei Liang; Kang Lu; Xiao-Juan Zhu; Yan-Xia Liu; Feng Zhang; Ting Yuan; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

6.  Interleukin-6 promotes carcinogenesis through multiple signal pathways. Comment on: Clinical significance of interleukin-6 gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Jiezhong Chen; Xu-Feng Huang
Journal:  Dig Dis Sci       Date:  2009-04-01       Impact factor: 3.199

7.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jing Deng; Adrian Wiestner; Brian J Lannutti; Lili Wang; Catherine J Wu; Wyndham H Wilson; Jennifer R Brown; Anthony Letai
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.

Authors:  William K Decker; Nina Shah; Dongxia Xing; Ruth Lapushin; Sufang Li; Simon N Robinson; Hong Yang; Simrit Parmar; Matthew M Halpert; Michael J Keating; John G Gribben; Jeffrey J Molldrem; Elizabeth J Shpall; William G Wierda
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

Review 9.  Beta-glucans in the treatment of diabetes and associated cardiovascular risks.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Vasc Health Risk Manag       Date:  2008

10.  The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.

Authors:  Wen-Liang Fang; Ming-Huang Chen; Kuo-Hung Huang; Chien-Hsing Lin; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Yi-Ming Shyr
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.